BioMotiv
Accelerating Breakthrough Discoveries into Medicines

News

News

Takeda, HDI Partner to Advance Rare Diseases Treatments

Harrington Discovery Institute (HDI) and Takeda Pharmaceuticals have teamed up to support the translation of research into treatments for rare diseases. The alliance builds on HDI’s model and results in a dedicated rare-disease funding track that will benefit from Takeda’s capabilities. Takeda is also a strategic partner of BioMotiv.

Click here to read more.

NewsErin Reese